Form D · Biotechnology
GeoVax Labs, Inc.
Smyrna, GA · CIK 0000832489
Offering snapshot reported Jun 22, 2022 · SEC filing
- Reported sold
- $15M Offering amount: $15M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 25, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 22, 2022 | Initial | $15,000,000 | No comparison | 1 | SEC filing |
| Jan 20, 2022 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Feb 25, 2021 | Initial | $495,000 | No comparison | 1 | SEC filing |
| Oct 8, 2020 | Initial | $1,500,000 | No comparison | 8 | SEC filing |
| Jul 6, 2020 | Initial | $2,400,000 | No comparison | 2 | SEC filing |
| Nov 1, 2019 | Amendment | $700,000 | $0vs Nov 1, 2019 | 2 | SEC filing |
| Nov 1, 2019 | Amendment | $3,256,534 | $0vs Oct 31, 2019 | 2 | SEC filing |
| Nov 1, 2019 | Initial | $700,000 | No comparison | 2 | SEC filing |
| Oct 31, 2019 | Initial | $3,256,534 | No comparison | 2 | SEC filing |
| Dec 23, 2013 | Initial | $1,650,000 | No comparison | 3 | SEC filing |
| Apr 2, 2012 | Initial | $2,200,000 | No comparison | 3 | SEC filing |
| Jan 13, 2012 | Initial | $441,210 | No comparison | 15 | SEC filing |
| Sep 30, 2009 | Initial | $1,500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $900K
- Finders' fees
- $0
- Form D file number
- 021-449972
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Jun 22, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Antebi | Director |
| Randal D. Chase | Director |
| David A. Dodd | Director, Executive |
| Farshad Guirakhoo | Executive |
| Donald Hildebrand | Director |
| Dean G. Kollintzas | Director |
| Robert T. Mc Nally | Director |
| Mark J. Newman | Executive |
| Mark W. Reynolds | Executive |
| Harriet L. Robinson | Director |
| John N. Spencer | Director |
| John N. Spencer, Jr. | Director |
| Peter Tsolinas | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1900 Lake Park Drive Suite 380
Smyrna, GA, 30080
Smyrna, GA, 30080